Albireo Pharma, Inc. (ALBO) financial statements (2020 and earlier)
Company profile
| Business Address |
10 POST OFFICE SQUARE BOSTON, MA 02109 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 9/30/2016 | 9/30/2015 | 9/30/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 143 | 164 | 53 | 30 | 29 | 41 | 25 | ||
| Cash and cash equivalents | 143 | 164 | 53 | 30 | 29 | 41 | 25 | ||
| Receivables | 3 | 1 | 0 | 0 | |||||
| Other undisclosed current assets | 5 | 1 | 1 | 1 | 0 | 0 | 0 | ||
| Total current assets: | 148 | 168 | 55 | 31 | 29 | 41 | 25 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1 | 0 | 0 | 0 | 0 | 0 | |||
| Intangible assets, net (including goodwill) | 17 | 17 | 17 | 18 | 0 | 0 | 0 | ||
| Goodwill | 17 | 17 | 17 | 18 | |||||
| Intangible assets, net (excluding goodwill) | 0 | 0 | 0 | 0 | |||||
| Other noncurrent assets | 6 | 0 | 1 | 1 | |||||
| Total noncurrent assets: | 23 | 18 | 18 | 19 | 0 | 0 | 1 | ||
| TOTAL ASSETS: | 171 | 185 | 73 | 50 | 29 | 41 | 25 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 12 | 13 | 7 | 9 | 1 | 2 | 1 | ||
| Accounts payable | 3 | 4 | 1 | 1 | 0 | 0 | 0 | ||
| Accrued liabilities | 8 | 8 | 6 | 8 | 0 | 0 | 0 | ||
| Employee-related liabilities | 0 | 1 | 1 | ||||||
| Debt | 3 | ||||||||
| Derivative instruments and hedges, liabilities | 1 | ||||||||
| Restructuring reserve | 1 | ||||||||
| Other liabilities | 1 | 0 | 0 | 0 | |||||
| Other undisclosed current liabilities | 0 | 0 | 0 | 0 | |||||
| Total current liabilities: | 12 | 13 | 8 | 13 | 2 | 2 | 2 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 4 | ||||||||
| Operating lease, liability | 4 | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt, including: | 4 | 0 | 0 | 0 | 0 | ||||
| Other liabilities | 4 | 0 | 0 | 0 | |||||
| Other undisclosed liabilities, other than long-term debt | 0 | ||||||||
| Other undisclosed noncurrent liabilities | 49 | 50 | 0 | 0 | 1 | ||||
| Total noncurrent liabilities: | 57 | 50 | 0 | 0 | 0 | 1 | |||
| Total liabilities: | 70 | 63 | 8 | 13 | 2 | 2 | 3 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 102 | 123 | 65 | 37 | 26 | 40 | 23 | ||
| Preferred stock | 0 | ||||||||
| Common stock | 0 | 0 | 0 | 0 | 0 | 1 | |||
| Additional paid in capital | 243 | 215 | 115 | 61 | 288 | 287 | 252 | ||
| Accumulated other comprehensive income | 11 | 4 | 1 | 1 | |||||
| Accumulated deficit | (152) | (96) | (50) | (26) | (262) | (248) | |||
| Other undisclosed stockholders' equity attributable to parent | (229) | ||||||||
| Total stockholders' equity: | 102 | 123 | 65 | 37 | 26 | 40 | 23 | ||
| TOTAL LIABILITIES AND EQUITY: | 171 | 185 | 73 | 50 | 29 | 41 | 25 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 9/30/2016 | 9/30/2015 | 9/30/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue, net | ✕ | ✕ | 0 | 11 | 1 | |||
| Gross profit: | 4 | 13 | 0 | 11 | 1 | |||
| Operating expenses | (69) | (51) | (25) | (24) | (14) | (20) | (19) | |
| Operating loss: | (65) | (38) | (25) | (12) | (14) | (20) | (19) | |
| Nonoperating income (expense) | (1) | (3) | 0 | (3) | ||||
| Foreign currency transaction gain (loss), before tax | 0 | (5) | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (66) | (41) | (24) | (15) | (14) | (20) | (19) | |
| Other undisclosed income (loss) from continuing operations before income taxes | (2) | (5) | 0 | (1) | 0 | 1 | 5 | |
| Loss from continuing operations before income taxes: | (68) | (46) | (24) | (16) | (14) | (19) | (14) | |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | (0) | ||
| Other undisclosed loss from continuing operations | (0) | |||||||
| Net loss: | (68) | (46) | (24) | (16) | (14) | (19) | (14) | |
| Other undisclosed net loss attributable to parent | (3) | |||||||
| Net loss available to common stockholders, diluted: | (71) | (46) | (24) | (16) | (14) | (19) | (14) | |
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 9/30/2016 | 9/30/2015 | 9/30/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (68) | (46) | (24) | (16) | (14) | (19) | (14) | |
| Other comprehensive income (loss) | 6 | 3 | (0) | 1 | ||||
| Comprehensive loss: | (62) | (43) | (25) | (16) | (14) | (19) | (14) | |
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (3) | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (65) | (43) | (25) | (16) | (14) | (19) | (14) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.